This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jackson, L. A. Articles by Vaughan, T. L. Search for Related Content PubMed PubMed Citation Articles by Jackson, L. A. Articles by Vaughan, T. L.

Association of Chlamydia pneumoniae Immunoglobulin A Seropositivity and Risk of Lung Cancer

Departments of Epidemiology [L. A. J., J. T. G., T. L. V.] and Pathobiology [S-P. W., J. T. G.], School of Public Health and Community Medicine, University of Washington; Center for Health Studies [L. A. J.], Group Health Cooperative of Puget Sound; and Program in Epidemiology [V. N-S., T. L. V.], Fred Hutchinson Cancer Research Center, Seattle, Washington 98101

Chlamydia pneumoniae is a common respiratory pathogen that has also been associated with risk for chronic diseases, including atherosclerotic cardiovascular disease. Two recent studies have reported an association between serological evidence of past infection with the organism and lung cancer. To further evaluate this association, we conducted a case-control study among a subgroup of white male smokers identified for a population-based case-control study of lung cancer in western Washington between 1993 and 1995. Serum specimens obtained at study enrollment from 143 cases and 147 controls were tested for C. pneumoniae IgG, IgM, and IgA antibodies. In multivariate analysis controlling for smoking variables and educational status, IgA antibody titer 16 was independently associated with risk of lung cancer among subjects <60 years of age [odds ratio (OR), 2.67; 95% confidence interval (CI), 1.21–5.89] but not among older subjects (OR, 0.69; 95% CI, 0.34–1.43). Among subjects <60 years of age, there was suggestive evidence of a stronger association among current smokers (OR 4.31; 95% CI, 1.36–13.68) than former smokers (OR 1.50; 95% CI, 0.48–4.75; P for interaction term, 0.26). Additional studies, including prospective serological evaluations, are needed to further assess the possible significance of this association.

This article has been cited by other articles:

				A. J. Littman, L. A. Jackson, and T. L. Vaughan Chlamydia pneumoniae and Lung Cancer: Epidemiologic Evidence Cancer Epidemiol. Biomarkers Prev., April 1, 2005; 14(4): 773 - 778. [Abstract] [Full Text] [PDF]

				A. J. Littman, E. White, L. A. Jackson, M. D. Thornquist, C. A. Gaydos, G. E. Goodman, and T. L. Vaughan Chlamydia pneumoniae Infection and Risk of Lung Cancer Cancer Epidemiol. Biomarkers Prev., October 1, 2004; 13(10): 1624 - 1630. [Abstract] [Full Text] [PDF]

				B. Kocazeybek Chronic Chlamydophila pneumoniae infection in lung cancer, a risk factor: a case-control study J. Med. Microbiol., August 1, 2003; 52(8): 721 - 726. [Abstract] [Full Text] [PDF]

				C. Sweeney, V. Nazar-Stewart, P. L. Stapleton, D. L. Eaton, and T. L. Vaughan Glutathione S-transferase M1, T1, and P1 Polymorphisms and Survival among Lung Cancer Patients Cancer Epidemiol. Biomarkers Prev., June 1, 2003; 12(6): 527 - 533. [Abstract] [Full Text] [PDF]

				T. D. Read, G. S. A. Myers, R. C. Brunham, W. C. Nelson, I. T. Paulsen, J. Heidelberg, E. Holtzapple, H. Khouri, N. B. Federova, H. A. Carty, et al. Genome sequence of Chlamydophila caviae (Chlamydia psittaci GPIC): examining the role of niche-specific genes in the evolution of the Chlamydiaceae Nucleic Acids Res., April 15, 2003; 31(8): 2134 - 2147. [Abstract] [Full Text] [PDF]

				M. Paldanius, A. Bloigu, M. Leinonen, and P. Saikku Measurement of Chlamydia pneumoniae-Specific Immunoglobulin A (IgA) Antibodies by the Microimmunofluorescence (MIF) Method: Comparison of Seven Fluorescein-Labeled Anti-Human IgA Conjugates in an In-House MIF Test Using One Commercial MIF and One Enzyme Immunoassay Kit Clin. Vaccine Immunol., January 1, 2003; 10(1): 8 - 12. [Abstract] [Full Text] [PDF]

				G. Falck, J. Gnarpe, L.-O. Hansson, K. Svardsudd, and H. Gnarpe Comparison of Individuals With and Without Specific IgA Antibodies to Chlamydia pneumoniae: Respiratory Morbidity and the Metabolic Syndrome Chest, November 1, 2002; 122(5): 1587 - 1593. [Abstract] [Full Text] [PDF]